オルニチントランスカルバミラーゼ欠損症（OTC欠損症）の世界市場レポート 2025年

オルニチントランスカルバミラーゼ欠損症（OTC欠損症）市場規模は、今後数年間で力強い成長が見込まれます。2029年には11億6,000万米ドルに成長し、CAGRは6.8%となります。予測期間中の成長は、認知度と診断の向上、尿素サイクル障害の有病率の上昇、希少疾患治療への注目の高まり、研究と臨床試験の増加、治療への患者アクセスの改善などに起因すると考えられます。この期間の主な動向としては、遺伝子治療や遺伝子編集技術の発展、酵素補充療法の開発、共同研究の取り組みやパートナーシップ、診断ツールの技術革新、希少疾病治療薬に対する政府の資金援助や優遇措置などが挙げられます。

遺伝子治療に対する需要の増加は、オルニチントランスカルバミラーゼ欠損症市場の成長を促進すると予想されます。遺伝子治療は、病気の治療や予防のために人の遺伝物質を変化させる医療技術です。これらの治療に対する需要の高まりは、遺伝性疾患の有病率の上昇に関連しており、その多くは治療選択肢がほとんどないため、遺伝子治療は単に症状を緩和するだけでなく、症状の根本原因に対処する魅力的なアプローチとなっています。オルニチントランスカルバミラーゼ欠損症は、尿素サイクルを阻害する遺伝子変異を修正することで、代謝機能を回復させ、有害なアンモニアの蓄積を防ぐ標的ソリューションを提供し、遺伝子治療の可能性を浮き彫りにしています。例えば、2024年1月、米国遺伝子・細胞治療学会は、2023年第4四半期に第III相段階にある遺伝子治療薬の数が10％増加し、2022年第3四半期以来の増加となったと報告しました。このような遺伝子治療需要の伸びが、オルニチントランスカルバミラーゼ欠損症市場の拡大に寄与しています。

オルニチントランスカルバミラーゼ欠乏症市場に関与する企業は、治療成果を改善し、OTC欠乏症の遺伝的基盤に対処するために、mRNA治療薬などの革新的な治療にますます注力しています。mRNA治療薬は、メッセンジャーRNAを使用して、遺伝性疾患、感染症、がんなどの疾患を治療できる特定のタンパク質を産生するよう細胞に指示します。例えば、2023年6月、米国のバイオテクノロジー企業であるArcturus Therapeutics Holdings Inc.は、オルニチントランスカルバミラーゼ（OTC）欠乏症治療用のmRNA治療薬候補ARCT-810について、FDAからファスト・トラック指定を受けた。この指定は、開発と審査のプロセスを加速させることを目的としており、FDAとの頻繁なやり取りや優先審査などの利点があります。ARCT-810は、OTC欠乏症患者が肝細胞内で機能的なOTC酵素を産生するのを助けるよう設計されており、症状の根本的な原因に対処し、QOLを改善する可能性があります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のオルニチントランスカルバミラーゼ欠損症（OTC欠損症） PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のオルニチントランスカルバミラーゼ欠損症（OTC欠損症）市場：成長率分析
• 世界のオルニチントランスカルバミラーゼ欠損症（OTC欠損症）市場の実績：規模と成長、2019年～2024年
• 世界のオルニチントランスカルバミラーゼ欠損症（OTC欠損症）市場の予測：規模と成長、2024年～2029年、2034年
• 世界のオルニチントランスカルバミラーゼ欠損症（OTC欠損症）総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のオルニチントランスカルバミラーゼ欠損症（OTC欠損症）市場：製品タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• DTX-301
• SEL-313
• SHP-641
• PRX-OTC
• 世界のオルニチントランスカルバミラーゼ欠損症（OTC欠損症）市場：治療タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 遺伝子治療
• 肝臓移植
• 食事管理
• その他の治療タイプ
• 世界のオルニチントランスカルバミラーゼ欠損症（OTC欠損症）市場：診断別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 遺伝子検査
• アンモニア濃度検査
• 世界のオルニチントランスカルバミラーゼ欠損症（OTC欠損症）市場：エンドユーザー別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 病院
• 専門クリニック
• 研究機関
• その他のエンドユーザー
• 世界のオルニチントランスカルバミラーゼ欠損症（OTC欠損症）市場、DTX-301のサブセグメンテーション（タイプ別）、実績と予測、2019年～2024年、2024年～2029年、2034年
• アデノ随伴ウイルス（AAV）を用いた遺伝子治療
• 静脈内投与製剤
• 世界のオルニチントランスカルバミラーゼ欠損症（OTC欠損症）市場、SEL-313のサブセグメンテーション（タイプ別）、実績と予測、2019年～2024年、2024年～2029年、2034年
• 免疫寛容誘導療法
• 酵素補充療法（ERT）併用療法
• 世界のオルニチントランスカルバミラーゼ欠損症（OTC欠損症）市場、SHP-641のサブセグメンテーション（タイプ別）、実績と予測、2019年～2024年、2024年～2029年、2034年
• 小分子療法
• mRNAベースの治療アプローチ
• 世界のオルニチントランスカルバミラーゼ欠損症（OTC欠損症）市場、PRX-OTCの種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• 組換え酵素補充療法
• タンパク質工学に基づく治療法

第7章 地域別・国別分析

• 世界のオルニチントランスカルバミラーゼ欠損症（OTC欠損症）市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 世界のオルニチントランスカルバミラーゼ欠損症（OTC欠損症）市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• オルニチントランスカルバミラーゼ欠損症（OTC欠損症）市場：競合情勢
• オルニチントランスカルバミラーゼ欠損症（OTC欠損症）市場：企業プロファイル
  • Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Amgen Inc.
• Merck & Co. Inc
• Biogen Idec
• Bausch Health Companies Inc
• Alexion Pharmaceuticals
• Sobi
• BioMarin Pharmaceutical Inc
• Glenmark Pharmaceuticals Ltd.
• Nutricia
• Vertex Pharmaceuticals Incorporated
• Ultragenyx Pharmaceutical Inc
• Arcturus Therapeutics
• Regenxbio
• OrphanPacific Inc
• Ucyclyd Pharma Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• オルニチントランスカルバミラーゼ欠損症（OTC欠損症）市場2029年：新たな機会を提供する国
• オルニチントランスカルバミラーゼ欠損症（OTC欠損症）市場2029年：新たな機会を提供するセグメント
• オルニチントランスカルバミラーゼ欠損症（OTC欠損症）市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Ornithine transcarbamylase (OTC) deficiency is a rare genetic disorder caused by mutations in the OTC gene, leading to a lack of the ornithine transcarbamylase enzyme, which is crucial for the urea cycle to remove ammonia from the body. This deficiency results in hyperammonemia, which can cause symptoms such as vomiting, lethargy, seizures, and in severe cases, coma, particularly in newborns.

The main product types for treating OTC deficiency include DTX-301, SEL-313, SHP-641, and PRX-OTC. DTX-301 is an investigational AAV8-based gene therapy designed to deliver a functional OTC gene to liver cells for treating OTC deficiency. Treatment options include gene therapy, liver transplant, dietary management, and other therapies. Diagnosis is performed using genetic testing and ammonia level testing. The end users of OTC deficiency treatments include hospitals, specialty clinics, research institutes, and other healthcare providers.

The ornithine transcarbamylase deficiency (OTC deficiency) market research report is one of a series of new reports from The Business Research Company that provides ornithine transcarbamylase deficiency (OTC deficiency) market statistics, including the ornithine transcarbamylase deficiency (OTC deficiency) industry global market size, regional shares, competitors with the ornithine transcarbamylase deficiency (OTC deficiency) market share, detailed ornithine transcarbamylase deficiency (OTC deficiency) market segments, market trends, and opportunities, and any further data you may need to thrive in the ornithine transcarbamylase deficiency (OTC deficiency) industry. This ornithine transcarbamylase deficiency (OTC deficiency) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The ornithine transcarbamylase deficiency (OTC deficiency) market size has grown strongly in recent years. It will grow from $0.83 billion in 2024 to $0.89 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth during the historic period can be attributed to increased awareness of rare metabolic disorders, advancements in genetic screening and diagnostics, improvements in neonatal screening programs, the rising prevalence of genetic testing for rare diseases, and enhanced neonatal screening initiatives.

The ornithine transcarbamylase deficiency (OTC deficiency) market size is expected to see strong growth in the next few years. It will grow to $1.16 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth during the forecast period can be attributed to increasing awareness and diagnosis, the rising prevalence of urea cycle disorders, a growing focus on rare disease treatments, more research and clinical trials, and improved patient access to treatments. Key trends during this period include advancements in genetic therapies and gene editing technologies, the development of enzyme replacement therapies, collaborative research initiatives and partnerships, technological innovations in diagnostic tools, and government funding and incentives for orphan drugs.

The increasing demand for gene therapies is expected to drive the growth of the ornithine transcarbamylase deficiency market. Gene therapy is a medical technique that involves altering a person's genetic material to treat or prevent diseases. The growing demand for these therapies is linked to the rising prevalence of genetic disorders, many of which have few treatment options, making gene therapy an appealing approach to address the root cause of the condition rather than just alleviating symptoms. Ornithine transcarbamylase deficiency highlights the potential of gene therapy by correcting the genetic mutation that disrupts the urea cycle, offering a targeted solution that restores metabolic function and prevents harmful ammonia buildup. For example, in January 2024, the American Society of Gene & Cell Therapy reported that the number of gene therapies in Phase III increased by 10% in Q4 2023, the first increase since Q3 2022. This growth in gene therapy demand is thus contributing to the expansion of the ornithine transcarbamylase deficiency market.

Companies involved in the ornithine transcarbamylase deficiency market are increasingly focusing on innovative therapies such as mRNA therapeutics to improve treatment outcomes and address the genetic basis of OTC deficiency. mRNA therapeutics use messenger RNA to instruct cells to produce specific proteins that can treat diseases, including genetic disorders, infections, and cancers. For instance, in June 2023, Arcturus Therapeutics Holdings Inc., a U.S.-based biotech firm, received Fast Track Designation from the FDA for its mRNA therapeutic candidate, ARCT-810, for treating ornithine transcarbamylase (OTC) deficiency. This designation aims to accelerate the development and review process, providing benefits such as more frequent interactions with the FDA and priority review. ARCT-810 is designed to help OTC deficiency patients produce a functional OTC enzyme in their liver cells, addressing the underlying cause of the condition and potentially improving their quality of life.

In November 2023, Zevra Therapeutics Inc., a U.S.-based pharmaceutical company, acquired Acer Therapeutics Inc. for $91 million. This acquisition strengthens Zevra Therapeutics' position in the rare disease sector, expanding its portfolio and increasing its revenue potential. Acer Therapeutics specializes in developing therapies for ornithine transcarbamylase deficiency, further enhancing Zevra's focus in this therapeutic area.

Major players in the ornithine transcarbamylase deficiency (otc deficiency) market are Thermo Fisher Scientific, Novartis AG, GlaxoSmithKline plc, Roche Holding AG, Eli Lilly and Company, Amgen Inc., Merck & Co. Inc, Biogen Idec, Bausch Health Companies Inc, Alexion Pharmaceuticals, Sobi, BioMarin Pharmaceutical Inc, Glenmark Pharmaceuticals Ltd., Nutricia, Vertex Pharmaceuticals Incorporated, Ultragenyx Pharmaceutical Inc, Arcturus Therapeutics, Regenxbio, OrphanPacific Inc, Ucyclyd Pharma Inc.

North America was the largest region in the ornithine transcarbamylase deficiency (OTC Deficiency) market in 2024. Asia-pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ornithine transcarbamylase deficiency report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the ornithine transcarbamylase deficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ornithine transcarbamylase deficiency market consists of revenues earned by entities by providing services such as genetic testing & diagnosis services, dietary management & nutrition services, clinical trials & research programs, medical consultation and genetic counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The ornithine transcarbamylase deficiency (OTC deficiency) market also includes sales of amino acid and protein supplements, gene therapies, nitrogen scavenging drugs, diagnostic and monitoring tests. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ornithine Transcarbamylase Deficiency (OTC Deficiency) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ornithine transcarbamylase deficiency (otc deficiency) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ornithine transcarbamylase deficiency (otc deficiency) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ornithine transcarbamylase deficiency (otc deficiency) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: DTX-301; SEL-313; SHP-641; PRX-OTC
• 2) By Treatment Type: Gene Therapy; Liver Transplant; Dietary Management; Other Treatement Type
• 3) By Diagnosis: Genetic Testing; Ammonia Level Testing
• 4) By End-User: Hospitals; Specialty Clinics; Research Institutes; Other End Users
• Sub Segments:
• 1) By DTX-301: Adeno-Associated Virus (AAV)-Based Gene Therapy; Intravenous Dosing Formulation
• 2) By SEL-313: Immune Tolerance-Inducing Therapy; Enzyme Replacement Therapy (ERT) Combination
• 3) By SHP-641: Small Molecule Therapy; mRNA-Based Therapeutic Approach
• 4) By PRX-OTC: Recombinant Enzyme Replacement Therapy; Protein Engineering-Based Therapy
• Companies Mentioned: Thermo Fisher Scientific; Novartis AG; GlaxoSmithKline plc; Roche Holding AG; Eli Lilly and Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Characteristics

3. Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Trends And Strategies

4. Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Ornithine Transcarbamylase Deficiency (OTC Deficiency) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Ornithine Transcarbamylase Deficiency (OTC Deficiency) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Growth Rate Analysis
• 5.4. Global Ornithine Transcarbamylase Deficiency (OTC Deficiency) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Ornithine Transcarbamylase Deficiency (OTC Deficiency) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Ornithine Transcarbamylase Deficiency (OTC Deficiency) Total Addressable Market (TAM)

6. Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Segmentation

• 6.1. Global Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• DTX-301
• SEL-313
• SHP-641
• PRX-OTC
• 6.2. Global Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gene Therapy
• Liver Transplant
• Dietary Management
• Other Treatement Type
• 6.3. Global Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Genetic Testing
• Ammonia Level Testing
• 6.4. Global Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Research Institutes
• Other End Users
• 6.5. Global Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Sub-Segmentation Of DTX-301, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adeno-Associated Virus (AAV)-Based Gene Therapy
• Intravenous Dosing Formulation
• 6.6. Global Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Sub-Segmentation Of SEL-313, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immune Tolerance-Inducing Therapy
• Enzyme Replacement Therapy (ERT) Combination
• 6.7. Global Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Sub-Segmentation Of SHP-641, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Small Molecule Therapy
• mRNA-Based Therapeutic Approach
• 6.8. Global Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Sub-Segmentation Of PRX-OTC, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Recombinant Enzyme Replacement Therapy
• Protein Engineering-Based Therapy

7. Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Regional And Country Analysis

• 7.1. Global Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market

• 8.1. Asia-Pacific Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market

• 9.1. China Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Overview
• 9.2. China Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market

• 10.1. India Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market

• 11.1. Japan Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Overview
• 11.2. Japan Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market

• 12.1. Australia Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market

• 13.1. Indonesia Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market

• 14.1. South Korea Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Overview
• 14.2. South Korea Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market

• 15.1. Western Europe Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Overview
• 15.2. Western Europe Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market

• 16.1. UK Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market

• 17.1. Germany Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market

• 18.1. France Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market

• 19.1. Italy Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market

• 20.1. Spain Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market

• 21.1. Eastern Europe Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Overview
• 21.2. Eastern Europe Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market

• 22.1. Russia Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market

• 23.1. North America Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Overview
• 23.2. North America Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market

• 24.1. USA Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Overview
• 24.2. USA Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market

• 25.1. Canada Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Overview
• 25.2. Canada Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market

• 26.1. South America Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Overview
• 26.2. South America Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market

• 27.1. Brazil Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market

• 28.1. Middle East Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Overview
• 28.2. Middle East Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market

• 29.1. Africa Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Overview
• 29.2. Africa Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Competitive Landscape And Company Profiles

• 30.1. Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Competitive Landscape
• 30.2. Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Company Profiles
  • 30.2.1. Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

31. Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Other Major And Innovative Companies

• 31.1. Amgen Inc.
• 31.2. Merck & Co. Inc
• 31.3. Biogen Idec
• 31.4. Bausch Health Companies Inc
• 31.5. Alexion Pharmaceuticals
• 31.6. Sobi
• 31.7. BioMarin Pharmaceutical Inc
• 31.8. Glenmark Pharmaceuticals Ltd.
• 31.9. Nutricia
• 31.10. Vertex Pharmaceuticals Incorporated
• 31.11. Ultragenyx Pharmaceutical Inc
• 31.12. Arcturus Therapeutics
• 31.13. Regenxbio
• 31.14. OrphanPacific Inc
• 31.15. Ucyclyd Pharma Inc.

32. Global Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market

34. Recent Developments In The Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market

35. Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market High Potential Countries, Segments and Strategies

• 35.1 Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Ornithine Transcarbamylase Deficiency (OTC Deficiency) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer